161 related articles for article (PubMed ID: 31268158)
21. Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression.
Tang CM; Lee TE; Syed SA; Burgoyne AM; Leonard SY; Gao F; Chan JC; Shi E; Chmielecki J; Morosini D; Wang K; Ross JS; Kendrick ML; Bardsley MR; Siena M; Mao J; Harismendy O; Ordog T; Sicklick JK
Oncotarget; 2016 Nov; 7(48):78226-78241. PubMed ID: 27793025
[TBL] [Abstract][Full Text] [Related]
22. Downregulation of CIC does not associate with overexpression of ETV1 or MAP kinase pathway activation in gastrointestinal stromal tumors.
Schoppmann SF; Ricken G; Ilhan-Mutlu A; Nirtl N; Streubel B; Preusser M; Birner P
Cancer Invest; 2014 Aug; 32(7):363-7. PubMed ID: 24897389
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.
Cohen NA; Zeng S; Seifert AM; Kim TS; Sorenson EC; Greer JB; Beckman MJ; Santamaria-Barria JA; Crawley MH; Green BL; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
Cancer Res; 2015 May; 75(10):2061-70. PubMed ID: 25836719
[TBL] [Abstract][Full Text] [Related]
24. Inhibitor of Apoptosis Proteins (IAPs) are commonly dysregulated in GIST and can be pharmacologically targeted to enhance the pro-apoptotic activity of imatinib.
Falkenhorst J; Grunewald S; Mühlenberg T; Marino-Enriquez A; Reis AC; Corless C; Heinrich M; Treckmann J; Podleska LE; Schuler M; Fletcher JA; Bauer S
Oncotarget; 2016 Jul; 7(27):41390-41403. PubMed ID: 27167336
[TBL] [Abstract][Full Text] [Related]
25. The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations.
Floris G; Sciot R; Wozniak A; Van Looy T; Wellens J; Faa G; Normant E; Debiec-Rychter M; Schöffski P
Clin Cancer Res; 2011 Sep; 17(17):5604-14. PubMed ID: 21737509
[TBL] [Abstract][Full Text] [Related]
26. Regorafenib for treatment of advanced gastrointestinal stromal tumors.
Overton LC; Heinrich MC
Expert Opin Pharmacother; 2014 Mar; 15(4):549-58. PubMed ID: 24405315
[TBL] [Abstract][Full Text] [Related]
27. GSTT1 copy number gain and ZNF overexpression are predictors of poor response to imatinib in gastrointestinal stromal tumors.
Lee EJ; Kang G; Kang SW; Jang KT; Lee J; Park JO; Park CK; Sohn TS; Kim S; Kim KM
PLoS One; 2013; 8(10):e77219. PubMed ID: 24124608
[TBL] [Abstract][Full Text] [Related]
28. Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature.
Prakash S; Sarran L; Socci N; DeMatteo RP; Eisenstat J; Greco AM; Maki RG; Wexler LH; LaQuaglia MP; Besmer P; Antonescu CR
J Pediatr Hematol Oncol; 2005 Apr; 27(4):179-87. PubMed ID: 15838387
[TBL] [Abstract][Full Text] [Related]
29. The role of KIT in the management of patients with gastrointestinal stromal tumors.
Hornick JL; Fletcher CD
Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
[TBL] [Abstract][Full Text] [Related]
30. Genomic and transcriptomic analysis of imatinib resistance in gastrointestinal stromal tumors.
Takahashi T; Elzawahry A; Mimaki S; Furukawa E; Nakatsuka R; Nakamura H; Nishigaki T; Serada S; Naka T; Hirota S; Shibata T; Tsuchihara K; Nishida T; Kato M
Genes Chromosomes Cancer; 2017 Apr; 56(4):303-313. PubMed ID: 27997714
[TBL] [Abstract][Full Text] [Related]
31. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
Demetri GD
Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
[TBL] [Abstract][Full Text] [Related]
32. The BRAF Status May Predict Response to Sorafenib in Gastrointestinal Stromal Tumors Resistant to Imatinib, Sunitinib, and Regorafenib: Case Series and Review of the Literature.
Franck C; Rosania R; Franke S; Haybaeck J; Canbay A; Venerito M
Digestion; 2019; 99(2):179-184. PubMed ID: 30179868
[TBL] [Abstract][Full Text] [Related]
33. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
34. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.
Bauer S; Duensing A; Demetri GD; Fletcher JA
Oncogene; 2007 Nov; 26(54):7560-8. PubMed ID: 17546049
[TBL] [Abstract][Full Text] [Related]
35. Insights into ligand stimulation effects on gastro-intestinal stromal tumors signalling.
Bahlawane C; Schmitz M; Letellier E; Arumugam K; Nicot N; Nazarov PV; Haan S
Cell Signal; 2017 Jan; 29():138-149. PubMed ID: 27777072
[TBL] [Abstract][Full Text] [Related]
36. Biomarkers and novel therapeutic targets in gastrointestinal stromal tumors (GISTs).
Campanella NC; de Oliveira AT; Scapulatempo-Neto C; Guimarães DP; Reis RM
Recent Pat Anticancer Drug Discov; 2013 Sep; 8(3):288-97. PubMed ID: 23198834
[TBL] [Abstract][Full Text] [Related]
37. FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors.
Li F; Huynh H; Li X; Ruddy DA; Wang Y; Ong R; Chow P; Qiu S; Tam A; Rakiec DP; Schlegel R; Monahan JE; Huang A
Cancer Discov; 2015 Apr; 5(4):438-51. PubMed ID: 25673643
[TBL] [Abstract][Full Text] [Related]
38. Gastrointestinal stromal tumors: molecular markers and genetic subtypes.
Barnett CM; Corless CL; Heinrich MC
Hematol Oncol Clin North Am; 2013 Oct; 27(5):871-88. PubMed ID: 24093165
[TBL] [Abstract][Full Text] [Related]
39. Mutational Testing in Gastrointestinal Stromal Tumor.
Wang Y; Call J
Curr Cancer Drug Targets; 2019; 19(9):688-697. PubMed ID: 30914028
[TBL] [Abstract][Full Text] [Related]
40. LIX1 regulates YAP activity and controls gastrointestinal cancer cell plasticity.
Guérin A; Martire D; Trenquier E; Lesluyes T; Sagnol S; Pratlong M; Lefebvre E; Chibon F; de Santa Barbara P; Faure S
J Cell Mol Med; 2020 Aug; 24(16):9244-9254. PubMed ID: 32633461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
